GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BB Biotech AG (LSE:0JYO) » Definitions » Gross Margin %

BB Biotech AG (LSE:0JYO) Gross Margin % : 0.00% (As of Mar. 2024)


View and export this data going back to . Start your Free Trial

What is BB Biotech AG Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. BB Biotech AG's Gross Profit for the three months ended in Mar. 2024 was €271.5 Mil. BB Biotech AG's Revenue for the three months ended in Mar. 2024 was €271.5 Mil. Therefore, BB Biotech AG's Gross Margin % for the quarter that ended in Mar. 2024 was 0.00%. If there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.


The historical rank and industry rank for BB Biotech AG's Gross Margin % or its related term are showing as below:


LSE:0JYO's Gross Margin % is not ranked *
in the Biotechnology industry.
Industry Median: 60.9
* Ranked among companies with meaningful Gross Margin % only.

BB Biotech AG had a gross margin of N/A% for the quarter that ended in Mar. 2024 => No sustainable competitive advantage

The 5-Year average Growth Rate of Gross Margin for BB Biotech AG was 0.00% per year.


BB Biotech AG Gross Margin % Historical Data

The historical data trend for BB Biotech AG's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BB Biotech AG Gross Margin % Chart

BB Biotech AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

BB Biotech AG Quarterly Data
Sep16 Dec16 Mar17 Jun17 Dec17 Dec18 Dec19 Dec20 Mar21 Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of BB Biotech AG's Gross Margin %

For the Biotechnology subindustry, BB Biotech AG's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BB Biotech AG's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BB Biotech AG's Gross Margin % distribution charts can be found below:

* The bar in red indicates where BB Biotech AG's Gross Margin % falls into.



BB Biotech AG Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

BB Biotech AG's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )=Gross Profit (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=-211.6 / -211.613
=(Revenue - Cost of Goods Sold) / Revenue
=(-211.613 - 0) / -211.613
=N/A %

BB Biotech AG's Gross Margin for the quarter that ended in Mar. 2024 is calculated as


Gross Margin % (Q: Mar. 2024 )=Gross Profit (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=271.5 / 271.535
=(Revenue - Cost of Goods Sold) / Revenue
=(271.535 - 0) / 271.535
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


BB Biotech AG  (LSE:0JYO) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

BB Biotech AG had a gross margin of N/A% for the quarter that ended in Mar. 2024 => No sustainable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


BB Biotech AG Gross Margin % Related Terms

Thank you for viewing the detailed overview of BB Biotech AG's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


BB Biotech AG (LSE:0JYO) Business Description

Traded in Other Exchanges
Address
Schwertstrasse 6, Schaffhausen, CHE, CH-8200
BB Biotech AG is a part of the healthcare sector in Switzerland. Its primary activity includes making investments, especially in the biotechnology market and is one of the largest investors in the field of biotechnology. The focus of the investments is on those listed companies that focus on the development and marketing of novel drugs with a clear value for the healthcare system. BB Biotech follows a strategy of carefully screening and selecting biotechnology firms with a long-term time horizon and having established products in the marketplace. Geographically it earns key revenue from the Netherlands.

BB Biotech AG (LSE:0JYO) Headlines

No Headlines